Drug Type Small molecule drug |
Synonyms Evocalcet (JAN/INN), 伊万卡塞 + [5] |
Target |
Mechanism CaSR agonists(Calcium sensing receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date JP (23 Mar 2018), |
Regulation- |
Molecular FormulaC24H26N2O2 |
InChIKeyRZNUIYPHQFXBAN-XLIONFOSSA-N |
CAS Registry870964-67-3 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Hypercalcemia | JP | 20 Dec 2019 | |
Hyperparathyroidism, Primary | JP | 20 Dec 2019 | |
Parathyroid Neoplasms | JP | 20 Dec 2019 | |
Hyperparathyroidism, Secondary | JP | 23 Mar 2018 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hyperparathyroidism, Secondary | Phase 3 | HK | 09 Apr 2019 | |
Chronic Kidney Diseases | Phase 3 | CN | 13 Feb 2019 |
Not Applicable | - | sckihhdxxu(tcienynwti) = zhuiyndngb qjbtayryso (zvekvzgxvg ) View more | Positive | 03 Nov 2022 | |||
sckihhdxxu(tcienynwti) = hqaxhqphgh qjbtayryso (zvekvzgxvg ) View more | |||||||
Phase 3 | Hyperparathyroidism, Secondary iPTH level | - | qmktjnbpxb(fbjkyonsrd) = wtdznjohtu lmwyutotzi (twskuzibqo ) View more | Positive | 03 Nov 2022 | ||
qmktjnbpxb(fbjkyonsrd) = hpceevlupb lmwyutotzi (twskuzibqo ) View more | |||||||
Phase 3 | 634 | vfdjdauwsh(bzllukhzcq) = demonstrated similar trends slgphujcsy (oxoamrtqpb ) View more | - | 01 Jan 2022 | |||
Phase 3 | 18 | tqonpfbwwx(tqbxdcofcl) = rsfarcazwv ihnvalugjm (giuchechxj, ugtpoggskw - krhdggcsbp) View more | - | 27 May 2021 | |||
Phase 3 | 18 | (lmjgseiqqy) = cvweczfxrp ffoffzkqoz (xokxjvddwu, 52.4 - 93.6) View more | Positive | 01 Sep 2020 | |||
Not Applicable | - | 34 | (dqfpmtabyf) = occurred in 2 patients nwtdhiezhk (ogbovwgzog ) View more | Positive | 06 Jun 2020 | ||
Phase 3 | - | 39 | (gtbjpodhqd) = Adverse drug reactions occurred in 46.2% (18/39) of patients, with most being of mild-to-moderate severity including GI-related events ofoevcdipf (sayxxvdrfp ) | Positive | 01 Jun 2019 | ||
NCT02549391 (Pubmed) Manual | Phase 3 | 634 | (tfjbrqgtuv) = kszfflxtjh iyloeknuir (npznoxmakb ) View more | Non-superior | 01 Oct 2018 | ||
(tfjbrqgtuv) = hqeddbqwwk iyloeknuir (npznoxmakb ) View more |